Organigram Global (OGI) Stock Price & Analysis
OGI Stock Chart & Stats
- Day’s Range
- $0.87 - $0.94
- 52-Week Range
- $0.85 - $2.24
- Previous Close
- $0.93
- Volume
- N/A
- Average Volume (3M)
- 544.94K
- Market Cap
- $127.88M
- Enterprise Value
- $217.07M
- Total Cash (Recent Filing)
- $11.67M
- Total Debt (Recent Filing)
- $31.45M
- Price to Earnings (P/E)
- 1.9
- Beta
- 1.13
- Next Earnings
- Dec 22, 2026 (Est.)
- EPS Estimate
- 0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin Growth
Strong quarterly growth combined with substantial adjusted margin expansion indicates improving scale and operating execution. If sustained, higher revenue and gross profit can strengthen reinvestment capacity, support brand development, and move the business toward more durable operating profitability.
Market Share And Product Position
Meaningful Canadian category shares, including leadership in concentrates, demonstrate established consumer demand and competitive product positioning. Continued share gains across flower, beverages, vapes, and infused pre-rolls could reinforce distribution relevance and improve the durability of domestic revenue.
Low Financial Leverage
Very low leverage reduces interest and refinancing pressure relative to a more debt-heavy capital structure. Growing equity and assets also provide greater financial flexibility to fund operations, integrate businesses, and manage volatility while the company works toward consistent cash generation.
Bears Say
Weak Core Profitability
Negative gross and operating margins show that the core business has not yet converted higher revenue into dependable operating earnings. This limits the company’s ability to self-fund growth and makes future profitability dependent on sustained pricing, mix, and efficiency improvements.
Persistent Cash Burn
Ongoing operating and free cash outflows indicate that reported performance is not yet translating into internally generated funding. Continued cash consumption can increase reliance on liquidity facilities or external capital and leaves less flexibility if integration costs or operating losses persist.
Pending EU-GMP Certification
The unresolved certification delays the company’s ability to fully control and scale compliant European supply from Moncton. Continued reliance on external processors and constrained EU-GMP flower availability may limit international growth, pressure margins, and complicate execution in Germany.
Organigram Global News
OGI FAQ
What was Organigram Global’s price range in the past 12 months?
What is Organigram Global’s market cap?
When is Organigram Global’s upcoming earnings report date?
How were Organigram Global’s earnings last quarter?
Is Organigram Global overvalued?
Does Organigram Global pay dividends?
What is Organigram Global’s EPS estimate?
How many shares outstanding does Organigram Global have?
What happened to Organigram Global’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Organigram Global?
What is the TipRanks Smart Score and how is it calculated?
Organigram Global Stock Smart Score
Company Description
Organigram Global
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- James Yamanaka
- Employees
- 1,139
- Website
- www.organigram.ca
- Address
- 145 King Street West, Toronto, ON, M5H 1J8, CA
Organigram Global (OGI) Earnings & Revenues
OGI Company Deck
OGI Earnings Call
Earnings Call SentimentPositive
The call communicated strong operational and financial momentum driven largely by the Sanity acquisition: record revenue, margin expansion, record adjusted EBITDA, and meaningful international diversification. Operational improvements in cultivation and category share gains in Canada reinforce the positive narrative. Key risks include negative free cash flow driven by working capital build, pending EU-GMP certification and tight EU-GMP supply into Germany, earlier vape/pre-roll quality issues in Canada, and U.S. regulatory uncertainty. Net income was materially boosted by non-cash fair value gains, so underlying cash generation and integration-related working capital remain focal concerns. On balance, the positive financial results, strategic diversification, and improving margin trajectory outweigh the liquidity and regulatory challenges discussed.
View all OGI earnings summariesOGI Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |











